Semaphorin‐3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C(+) and CD4(+)CD25(−) T‐cells

Autor: Hongxing Wang, Kunal Kapoor, Laëtitia Kermarrec, Jean-Eric Ghia, Abdelilah S. Gounni, Charles N. Bernstein, Abdoulaye Diarra, Nour Eissa
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Br J Pharmacol
Popis: BACKGROUND AND PURPOSE: An alteration in the communication between the innate and adaptive immune cells is a hallmark of ulcerative colitis (UC). Semaphorin‐3E (SEMA3E), a secreted guidance protein, regulates various immune responses. EXPERIMENTAL APPROACH: We investigated the expression of SEMA3E in colonic biopsies of active UC patients and its mechanisms in Sema3e (−/−) mice using an experimental model of UC. KEY RESULTS: SEMA3E level was decreased in active UC patients and negatively correlated with pro‐inflammatory mediators. Colonic expression of SEMA3E was reduced in colitic Sema3e (+/+) mice, and recombinant (rec‐) Plexin‐D1 treatment exacerbated disease severity. In vivo rec‐SEMA3E treatment restored SEMA3E level in colitic Sema3e (+/+) mice. In Sema3e (−/−) mice, disease severity was increased, and rec‐SEMA3E ameliorated these effects. Lack of Sema3e increased the expression of CD11c and CD86 markers. Colitic Sema3e (−/−) splenocytes and splenic CD11c(+) cells produced more IL‐12/23 and IFN‐γ compared to Sema3e (+/+), and rec‐SEMA3E reduced their release as much as NF‐κB inhibitors, whereas an NF‐κB activator increased their production and attenuated the effect of rec‐SEMA3E. Colitic Sema3e (−/−) splenic CD11c(+)/CD4(+)CD25(−) T‐cell co‐cultures produced higher concentrations of IFN‐γ and IL‐17 when compared to colitic Sema3e (+/+) splenic cell co‐cultures, and rec‐SEMA3E decreased these effects. In vitro, anti‐IL‐12p19 and ‐12p35 antibodies and rec‐IL‐12 and ‐23 treatment confirmed the crosstalk between CD11c(+) and CD4(+)CD25(−) T‐cells. CONCLUSION AND IMPLICATIONS: SEMA3E is reduced in colitis and modulates colonic inflammation by regulating the interaction between CD11c(+) and CD4(+)CD25(−) T‐cells via an NF‐κB‐dependent mechanism. Thus, SEMA3E could be a potential therapeutic target for UC patients.
Databáze: OpenAIRE